

# TUBEROUS SCLEROSIS ALLIANCE COLLABORATIVE RESEARCH INITIATIVES

Steven L. Roberds, PhD, Chief Scientific Officer



# TUBEROUS SCLEROSIS ALLIANCE (TS ALLIANCE)

The TS Alliance, founded in 1974, is committed to finding a cure for tuberous sclerosis complex while improving the lives of those affected:


- by developing programs, support services and resource information;
- by stimulating and sponsoring research; and
- by creating and implementing public and professional education programs designed to heighten awareness of the disease.



[www.tsalliance.org](http://www.tsalliance.org)


# TARGETED RESEARCH INITIATIVES AND COLLABORATION

*to accelerate discovery of new treatments and a cure*



# NATURAL HISTORY DATABASE STRATEGY 2016-18


*Sub-projects based on TSC constituents' research priorities*



# TSC BIOSAMPLE REPOSITORY

*Linked to clinical data in TSC Natural History Database (NHD)*

## Voluntary TSC NHD Participants



## Examples of Research Needs

- Understanding phenotypic heterogeneity
- Development of clinical biomarkers
- Patient-derived cells for drug testing

# TSC PRECLINICAL CONSORTIUM

*Key piece of TSC research strategy to accelerate drug discovery*

- Standardize models, tests and assays for preclinical drug development
  - Re-purpose compounds of interest
  - Test analogs with improved safety profiles
  - Investigate novel compounds and mechanisms of action
- Engage industry and increase opportunities for clinical trials
- Focus on Transparency, Robustness, Replication, Rigor and Translatability



# TSC PRECLINICAL CONSORTIUM

## *Industry screening buckets*

### Initial Commitment

#### Company Consortium Member

Access to all validation, phenotypic and reference compound results including raw data

### Screening Type

Public

Private

### Bucket

**Bucket A.** Reference compounds with results released to consortium. No IP implication.

**Bucket B.** Company's compound with results released to consortium. Escrow period to protect IP.

**Bucket C.** Company's compound with results not released to consortium. No strings attached.

# TSC CLINICAL RESEARCH CONSORTIUM

*Biomarker studies initiated in 2013 funded by NIH*



- Identify early markers of risk for autism in TSC (NINDS, NICHD)
- Identify early markers of risk for epilepsy in TSC (NINDS)
  - Regular EEG and imaging evaluation of 40 infants
  - Interim results published in October for 28 infants

	Clinical seizures	No clinical seizures
Abnormal EEG	14	0
Normal EEG	5	9

- Sensitivity-73.7%
- Specificity- 100%
- Positive Predictive Value (PPV)-100%
- Negative Predictive Value(NPV)--64%

Wu et al (2016) *Pediatr Neurol* 54:29-34



# PREVENTING EPILEPSY USING VIGABATRIN IN INFANTS WITH TUBEROUS SCLEROSIS COMPLEX (PREVeNT) TRIAL

- NINDS-funded Phase II study
- Projected start date: Fall 2016
- Multicenter: 7 sites across the US
- Study objective: impact of early versus delayed treatment with vigabatrin on development, assessed at 24 and 36 months of age

# ACKNOWLEDGING OUR PARTNERS AND COLLABORATORS

